Results 11 to 20 of about 43,436 (236)

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease [PDF]

New England Journal of Medicine, 2010
BACKGROUND: In autosomal dominant polycystic kidney disease (ADPKD), aberrant activation of the mammalian target of rapamycin (mTOR) pathway is associated with progressive kidney enlargement. The drug sirolimus suppresses mTOR signaling. METHODS: In this
Kistler, A D, Krauer, F, Kristanto, P, Poster, D, Raina, S, Rentsch, K M, Scheffel, H, Senn, O, Serra, A L, Spanaus, K S, Weishaupt, D, Wüthrich, R P, Young, J   +12 more
core   +3 more sources

Autosomal dominant polycystic kidney disease. [PDF]

Journal of the American Society of Nephrology, 1993
Autosomal dominant polycystic kidney disease (ADPKD) is an important cause of medical morbidity in the United States that affects one-half million persons and accounts for ESRD in about 10% of the chronic dialysis population. In addition to its effects on the kidney, the disease has important manifestations in the cardiovascular system (aneurysms ...
J C, Lieske, F G, Toback
openaire   +4 more sources

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

New England Journal of Medicine, 2012
V. Torres, A. Chapman, O. Devuyst, R. Gansevoort, J. Grantham, E. Higashihara, R. Perrone, H. Krasa, J. Ouyang, F. Czerwiec   +9 more
semanticscholar   +3 more sources

Autosomal dominant polycystic kidney disease [PDF]

Canadian Medical Association Journal, 2017
Mutations in PKD1 or PKD2 cause autosomal dominant polycystic kidney disease, which proceeds to kidney failure in 70% of patients between the fourth and seventh decade of life.[1][1] Signs of autosomal dominant polycystic kidney disease (i.e., numerous cysts and enlargement of the kidneys) may ...
Matthew B, Lanktree, Arlene B, Chapman
  +5 more sources

Tolvaptan in Later‐Stage Autosomal Dominant Polycystic Kidney Disease

New England Journal of Medicine, 2017
V. Torres, A. Chapman, O. Devuyst, R. Gansevoort, R. Perrone, G. Koch, J. Ouyang, R. Mcquade, J. Blais, F. Czerwiec, O. Sergeyeva   +10 more
semanticscholar   +3 more sources

Autosomal dominant polycystic kidney disease

Disease-a-Month, 2015
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disease of the kidneys that can cause an irreversible decline in kidney function leading to end-stage renal disease. It is one of the most common hereditary disorders. It is 10 times more common than sickle cell disease and 20 times more common than Huntington's disease.
Jonathan, Silverman, Chaitanya, Desai, Edgar V, Lerma   +2 more
  +8 more sources

Autosomal Dominant Polycystic Kidney Disease

Saudi Journal of Kidney Diseases and Transplantation, 1999
Schwenger Vedat, Zeier Martin
doaj   +2 more sources

Surgical Management of Autosomal Dominant Polycystic Kidney Disease: Principles and Current Practice

Journal of Nepal Medical Association, 2023
Autosomal dominant polycystic kidney disease is the third most common cause of renal failure with no definitive treatment available that can directly target the development and growth of the cysts.
Badri Man Shrestha
doaj   +1 more source

Polycystic Liver Disease: A Case Report

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 2021
Polycystic liver disease is characterized by multiple cystic lesions on the liver. Liver cysts are typically incidental findings, with occasional complications including cyst hemorrhage, infection and rupture.
Randy Adiwinata, Natalin Allorerung, Jonathan Arifputra, Andrea Livina, Pearla Lasut, Bradley Jimmy Waleleng, Fandy Gosal, Luciana Rotty, Jeanne Winarta, Andrew Waleleng, Michael Tendean   +10 more
doaj   +1 more source

Autosomal Dominant Polycystic Kidney Disease

Radiopaedia.org, 2012
Y. Glick, Townsville training
openaire   +2 more sources